Alberti KG, Zimmet P, Shaw J: IDF Epidemiology Task Force Consensus Group. The metabolic syndrome--a new worldwide definition. Lancet 2005, 366:1059–1062.
Isomaa B, Almgren P, Tuomi T, et al.: Cardiovascular morbidity and mortality associated with the metabolic syndrome. Diabetes Care 2001, 24:683–689.
Lakka HM, Laaksonen DE, Lakka TA, et al.: The metabolic syndrome and total and cardiovascular disease mortality in middle-aged men. JAMA 2002, 288:2709–2716.
Sundstrom J, Riserus U, Byberg L, et al.: Clinical value of the metabolic syndrome for long term prediction of total and cardiovascular mortality: prospective, population based cohort study. BMJ 2006, 332:878–882.
Reaven GM: Insulin resistance, the insulin resistance syndrome, and cardiovascular disease. Panminerva Med 2005, 47:201–210.
Kontush A, Chapman MJ: Antiatherogenic small, bddense HDL--guardian angel of the arterial wall?
Nat Clin Pract Cardiovasc Med 2006, 3:144–153.
Morse SA, Zhang R, Thakur V, Reisin E: Hypertension and the metabolic syndrome. Am J Med Sci 2005, 330:303–310.
Mule G, Cerasola G: The metabolic syndrome and its relationship to hypertensive target organ damage. J Clin Hypertens (Greenwich) 2006, 8:195–201.
Garcia-Puig J, Ruilope LM, Luque M, et al.: Glucose metabolism in patients with essential hypertension. Am J Med 2006, 119:318–326.
Alexander CM, Landsman PB, Teutsch SM, Haffner SM: Third National Health and Nutrition Examination Survey (NHANES III); National Cholesterol Education Program (NCEP). NCEP-defined metabolic syndrome, diabetes, and prevalence of coronary heart disease among NHANES III participants age 50 years and older. Diabetes 2003, 52:1210–1214.
Kahn R, Buse J, Ferrannini E, Stern M: American Diabetes Association; European Association for the Study of Diabetes. The metabolic syndrome: time for a critical appraisal: joint statement from the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care 2005, 28:2289–2304. The paper critically discusses the different aspects of the metabolic syndrome.
Sobel BE: Coronary artery disease and fibrinolysis: from the blood to the vessel wall. Thromb Haemost 1999, 82(Suppl 1):8–13.
Eckel RH, Grundy SM, Zimmet PZ: The metabolic syndrome. Lancet 2005, 365:1415–1428.
Bajzar L, Manuel R, Nesheim ME: Purification and characterization of TAFI, a thrombin-activable fibrinolysis inhibitor. J Biol Chem 1995, 270:14477–14484.
Aso Y, Wakabayashi S, Yamamoto R, et al.: Metabolic syndrome accompanied by hypercholesterolemia is strongly associated with proinflammatory state and impairment of fibrinolysis in patients with type 2 diabetes: synergistic effects of plasminogen activator inhibitor-1 and thrombin-activatable fibrinolysis inhibitor. Diabetes Care 2005, 28:2211–2216.
Sjoholm A, Nystrom T: Endothelial inflammation in insulin resistance. Lancet 2005, 365:610–612.
Ridker M, Buring JE, Cook NR, Rifai N: C-reactive protein, the metabolic syndrome, and risk of incident cardiovascular events: an 8-year follow-up of 14719 initially healthy American women. Circulation 2003, 107:391–397.
Rutter MK, Meigs JB, Sullivan LM, et al.: C-reactive protein, the metabolic syndrome, and prediction of cardiovascular events in the Framingham Offspring Study, Circulation 2004, 110:380–385.
Ford ES: The metabolic syndrome and C-reactive protein, fibrinogen, and leukocyte count: findings from the Third National Health and Nutrition Examination Survey. Atherosclerosis 2003, 168:351–358.
Zambon A, Pauletto P, Crepaldi G: Review article: the metabolic syndrome--a chronic cardiovascular inflammatory condition. Aliment Pharmacol Ther 2005, 22(Suppl 2):20–23.
Koh KK, Han SH, Quon MJ: Inflammatory markers and the metabolic syndrome: insights from therapeutic interventions. J Am Coll Cardiol 2005, 46:1978–1985.
Perseghin G: Muscle lipid metabolism in the metabolic syndrome. Curr Opin Lipidol 2005, 16:416–420.
Vigili de Kreutzenberg S, Kiwanuka E, Tiengo A, Avogaro A: Visceral obesity is characterized by impaired nitric oxideindependent vasodilation. Eur Heart J 2003, 24:1210–1215.
Cersosimo E, Defronzo RA: Insulin resistance and endothelial dysfunction: the road map to cardiovascular diseases. Diabetes Metab Res Rev 2006, in press.
Kim JA, Montagnani M, Koh KK, Quon MJ: Reciprocal relationships between insulin resistance and endothelial dysfunction: molecular and pathophysiological mechanisms. Circulation 2006, 113:1888–1904.
Bergman RN, Mittelman SD: Central role of the adipocyte in insulin resistance. J Basic Clin Physiol Pharmacol 1998, 9:205–221.
McCarty MF: AMPK activation as a strategy for reversing the endothelial lipotoxicity underlying the increased vascular risk associated with insulin resistance syndrome. Med Hypotheses 2005, 64:1211–1215.
Misra A, Vikram NK: Clinical and pathophysiological consequences of abdominal adiposity and abdominal adipose tissue depots. Nutrition 2003, 19:457–466.
Kabir M, Catalano KJ, Ananthnarayan S, et al.: Molecular evidence supporting the portal theory: a causative link between visceral adiposity and hepatic insulin resistance. Am J Physiol Endocrinol Metab 2005, 288:E454-E461.
Frayn KN: Visceral fat and insulin resistance-causative or correlative?
Br J Nutr 2000, 83:S71-S77.
Ahima RS, Flier JS: Adipose tissue as an endocrine organ. Trends Endocrinol Metab 2000, 11:327–332.
Okamoto Y, Kihara S, Funahashi T, et al.: Adiponectin: a key adipocytokine in metabolic syndrome. Clin Sci (Lond) 2006, 110:267–278.
Yamauchi T, Kamon J, Minokoshi Y, et al.: Adiponectin stimulates glucose utilization and fatty-acid oxidation by activating AMP-activated protein kinase. Nat Med 2002, 11:1288–1295.
Wu X, Motoshima H, Mahadev K, et al.: Involvement of AMP-activated protein kinase in glucose uptake stimulated by the globular domain of adiponectin in primary rat adipocytes. Diabetes 2003, 52:1355–1363.
Hotta K, Funahashi T, Arita Y, et al.: Plasma concentrations of a novel, adipose-specific protein, adiponectin, in type 2 diabetic patients. Arterioscler Thromb Vasc Biol 2000, 20:1595–1599.
Kumada M, Kihara S, Sumitsuji S, et al.: Association of hypoadiponectimia with coronary artery disease in men. Arterioscler Thromb Vasc Biol 2003, 23:85–89.
Rabin KR, Kamari Y, Avni I, et al.: Adiponectin: linking the metabolic syndrome to its cardiovascular consequences. Expert Rev Cardiovasc Ther 2005, 3:465–471.
Shimada K, Miyazaki T, Daida H: Adiponectin and atherosclerotic disease. Clin Chim Acta 2004, 344:1–12.
Ukkola O: Resistin - a mediator of obesity-associated insulin resistance or an innocent bystander?
Eur J Endocrinol 2002, 147:571–574.
Kaser S, Kaser A, Sandhofer A, et al.: Resistin messenger-RNA expression is increased by proinflammatory cytokines in vitro. Biochem Biophys Res Commun 2003, 309:286–290.
Lehrke M, Reilly MP, Millington SC, et al.: An inflammatory cascade leading to hyperresistinemia in humans. PLoS Med 2004, 1:e45.
Verma S, Li SH, Wang CH, et al.: Resistin promotes endothelial cell activation: Further evidence of adipokineendothelial interaction. Circulation 2003, 108:736–740.
Kunnari A, Ukkola O, Päivänsalo M, Kesäniemi YA: High plasma resistin level is associated with enhanced hs-CRP and leucocytes. J Clin Endocrinol Metab 2006, 91:2755–2760.
Matsuzawa Y: Therapy Insight: adipocytokines in metabolic syndrome and related cardiovascular disease. Nat Clin Pract Cardiovasc Med 2006, 3:35–42.
Hotamisligil GS: Mechanisms of TNF-á-induced insulin resistance. Exp Clin Endocrinol Diabetes 1999, 107:119–125.
Suganami T, Nishida J, Ogawa Y: A paracrine loop between adipocytes and macrophages aggravates inflammatory changes: role of free fatty acids and tumor necrosis factor alpha. Arterioscler Thromb Vasc Biol 2005, 25:2062–2068.
Lau DC, Dhillon B, Yan H, et al.: Adipokines: molecular links between obesity and atherosclerosis. Am J Physiol Heart Circ Physiol 2005, 288:H2031-H2041. An excellent and timely review of adipokines and their main characterictics.
Jacoby DS, Rader DJ: Renin-angiotensin system and atherothrombotic disease: from genes to treatment. Arch Intern Med 2003, 163:1155–1164.
De Taeye B, Smith LH, Vaughan DE: Plasminogen activator inhibitor-1: a common denominator in obesity, diabetes and cardiovascular disease. Curr Opin Pharmacol 2005, 5:149–154.
Yang RZ, Lee MJ, Hu H, et al.: Acute-phase serum amyloid A: an inflammatory adipokine and potential link between obesity and its metabolic complications. PLoS Med 2006, 3:e287.